HM17321 is a proprietary urocortin-2 (UCN2) analog peptide developed by Hanmi Pharm (KRX: 128940) that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2) for obesity treatment. The CRFR2 mechanism is distinct from every currently-approved obesity therapy (semaglutide, tirzepatide, orforglipron, and the broader GLP-1 class) and is designed to simultaneously promote weight loss and preserve lean body mass — addressing the muscle-loss concern that has emerged as the leading tolerability constraint on the current incretin class.
On Monday August 24, 2026, Hanmi Pharm signed an exclusive worldwide licensing agreement with Genentech (a member of the Roche Group) for HM17321. Deal terms: $190 million upfront payment plus up to $2.3 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales. Hanmi received FDA IND clearance in November 2025 to initiate the Phase 1 clinical trial and retains rights in South Korea; Genentech takes over from Phase 2 forward. Follow-through analyst commentary Tuesday August 25 positioned Roche as now targeting a top-three global obesity commercial position behind Eli Lilly and Novo Nordisk.
HM17321 is positioned as a potential first-in-class treatment designed to differentiate on the lean-mass-preservation axis, competing with the amylin analogs (Zealand-Roche petrelintide, AstraZeneca AZD6234, Metsera MET-233i) and the RNAi obesity candidates (Arrowhead ARO-INHBE, ARO-ALK7) in the muscle-preservation category. Stories here cover clinical readouts, deal milestones, and the broader non-incretin obesity pipeline. See #hanmi, #genentech, and #urocortin-2-crfr2 for adjacent threads.
The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting takes place in Milan September 28 through October 2, 2026, and sets up the largest single September catalyst window for obesity-peptide investor and clinical interest. AstraZeneca will present Phase 2 data on AZD6234 (selective amylin receptor peptide agonist) monotherapy from APRICUS plus the ASCEND Phase 2b combination with AZD9550 GLP-1/glucagon dual agonist. Zealand Pharma and Roche will present petrelintide (amylin analog) data from ZUPREME-2 (obesity plus type 2 diabetes) with the Phase 3 monotherapy program preparing to initiate late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD calendar coincides with the Roche Pharma Day investor event on Monday September 28, 2026 that will update on the top-three-obesity-portfolio (petrelintide, enicepatide, HM17321). Ascendis Pharma is also expected to provide TransCon CNP achondroplasia updates.
Roche (SIX: ROG) is scheduled to hold its investor Pharma Day Monday September 28, 2026, providing updates across the R&D portfolio including three obesity assets that collectively position the company as the credible third-place global obesity competitor behind Eli Lilly and Novo Nordisk. Petrelintide (amylin analog, partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, Phase 3 monotherapy initiation planned late 2026 following ZUPREME-1's 10.7% weight loss at 42 weeks). Enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2). HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties). The Roche Pharma Day coincides with the EASD 2026 Annual Meeting Milan September 28 through October 2, where AstraZeneca will present AZD6234 Phase 2 data, Zealand Pharma will present petrelintide data, and Novo Nordisk will present amycretin and CagriSema updates.
Roche (SIX: ROG) is scheduled to hold its Pharma Day investor event Monday September 28, 2026, providing updates across the R&D portfolio including three top-three-position obesity assets: petrelintide (amylin analog partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, ZUPREME-1 documented 10.7% weight loss at 42 weeks, Phase 3 monotherapy initiation planned late 2026); enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2); and HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties; Genentech takes over from Phase 2 forward). The Pharma Day briefing frames Roche as a credible third-place global obesity competitor behind Eli Lilly (Zepbound-Mounjaro-Foundayo plus upcoming retatrutide) and Novo Nordisk (Wegovy-Ozempic plus CagriSema plus amycretin), with EASD 2026 Milan September 28-October 2 the immediate downstream data catalyst.
Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP dual agonist peptide, in Kailera's global Phase 3 KaiNETIC program); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.
Follow-through analyst commentary Tuesday August 25, 2026 on the Monday Roche (SIX: ROG) and Hanmi Pharm HM17321 urocortin-2 (UCN2) obesity licensing deal positioned Roche as now targeting a top-three global obesity commercial position behind Eli Lilly (Zepbound, Mounjaro, Foundayo, and upcoming retatrutide) and Novo Nordisk (Wegovy, Ozempic, Wegovy Pill, Wegovy HD, CagriSema under review). Deal recap: $190 million upfront, up to $2.3 billion in milestones, plus tiered royalties; Genentech gets global rights excluding South Korea. HM17321 mechanism: a proprietary urocortin-2 (UCN2) analog peptide that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a mechanism distinct from the incretin pathway (GLP-1, GIP) that anchors every currently-approved obesity drug. Roche obesity portfolio positioning: HM17321 combines with Roche's existing CT-388 (a dual GIP/GLP-1 receptor agonist acquired in the December 2023 Carmot Therapeutics acquisition for $2.7 billion, currently in Phase 2 for obesity and type 2 diabetes) and the emerging Roche obesity pipeline including RG7500 orforglipron precursor and other early-stage assets. The multi-mechanism portfolio provides a differentiated commercial positioning to compete across weight-loss efficacy (Roche's incretin agonist candidates match Lilly and Novo) and muscle-preservation (HM17321's differentiated UCN2 mechanism designed for lean mass preservation). Roche's obesity ambition contrasts with prior investor skepticism about its late-cycle entry into the category; Tuesday's analyst commentary suggests the multi-mechanism strategy could position Roche credibly for 2028-2030 commercial launches assuming pipeline programs advance to registration.
Hanmi Pharm (KRX: 128940) signed Monday August 24, 2026 an exclusive licensing agreement with Genentech (a member of the Roche Group) for HM17321, a proprietary urocortin-2 (UCN2) analog peptide for obesity. Deal terms: $190 million upfront payment, up to $2.3 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales. Territory: Genentech secures global rights excluding South Korea, where Hanmi retains the license. Mechanism: HM17321 selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a peptide-hormone receptor pathway distinct from the incretin pathway (GLP-1 receptor, GIP receptor) that anchors every currently-approved obesity drug including semaglutide, tirzepatide, orforglipron, and the broader GLP-1 receptor agonist class. Urocortin-2 is a naturally occurring 38-amino-acid peptide of the corticotropin-releasing factor family. Differentiated profile: HM17321 is positioned as a potential first-in-class treatment designed to simultaneously promote weight loss and preserve lean body mass, an important differentiator against the semaglutide-tirzepatide-retatrutide GLP-1 class where roughly 25% of the total weight lost is lean muscle mass. Development pathway: Hanmi received FDA IND clearance to initiate a Phase 1 clinical trial in November 2025. Hanmi is responsible for completing the Phase 1 clinical trial, after which Genentech will take over development starting with Phase 2 clinical trials. The deal represents one of the largest 2026 obesity licensing transactions and adds a substantially different mechanism to Roche's obesity portfolio that also includes CT-388 (dual GIP/GLP-1 agonist from the Carmot Therapeutics acquisition).